ストックスクリーナーアプリを入手
6.96
1.16%
0.08
アフターアワーズ：
6.97
0.010
+0.14%
Novavax Inc (NVAX) 最新ニュース
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio - Yahoo
NVAX Stock Surges on Securing FDA Approval for COVID-19 Vaccine - MSN
Why Novavax Inc. stock attracts strong analyst attentionSolid Return Trade Selections - beatles.ru
BTIG Maintains a Buy Rating on Novavax (NVAX), Sets a $19 PT - MSN
Novavax (NVAX) Rises Higher Than Market: Key Facts - Yahoo Finance
Is Trending Stock Novavax, Inc. (NVAX) a Buy Now? - Yahoo Finance
Novavax's Dual Vaccine Strategy: Navigating Near-Term Hurdles to Long-Term Growth Potential - AInvest
Despite Revenue Jump, Novavax Appears Immune To Long-Term Growth (NASDAQ:NVAX) - Seeking Alpha
2 Beaten-Down Stocks That Haven't Hit Rock Bottom Yet - Yahoo Finance
Investor Alert: Kessler Topaz Meltzer & Check, LLP Reminds Novavax, Inc. (NVAX) Investors with Substantial Losses to Contact the Firm - ACCESS Newswire
(NVAX) Technical Data - news.stocktradersdaily.com
Citi Initiates Coverage of Novavax (NVAX) With a Sell Rating - MSN
Medical Groups Sue RFK Jr. For Assault On Science Over Unlawful COVID-19 Vaccine Rollbacks - Benzinga
Novavax (NVAX) Dips More Than Broader Market: What You Should Know - Yahoo Finance
RFK Jr. Influence Evident As Vaccine Chief Overrules Scientists, Limits COVID-19 Vaccine Approval - Benzinga
Is Most-Watched Stock Novavax, Inc. (NVAX) Worth Betting on Now? - Yahoo Finance
Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
Novavax Sees Sanofi Vaccine Pact as Model for Future Deals, Some Going Beyond Infectious Disease - MedCity News
Novavax Shareholders Approve Key Proposals at Annual Meeting - TipRanks
Novavax jumps 15% on COVID shot nod, among 14 FDA approvals in May - BioWorld MedTech
Novavax (NVAX) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Novavax (NVAX): Citi Downgrades to Sell Amid Pipeline Worries - GuruFocus
Novavax stock slips as Citi issues Sell rating (NVAX:NASDAQ) - Seeking Alpha
Insurers likely to cover vaccines without ACIP recommendations - Seeking Alpha
Novavax (NVAX) Coverage Initiated with 'Sell' Rating by Citigrou - GuruFocus
Novavax (NVAX) Coverage Initiated with 'Sell' Rating by Citigroup | NVAX Stock News - GuruFocus
Citi initiates Novavax stock with sell rating on strategy shift concerns - Investing.com UK
Novavax (NVAX) Receives Initial 'Sell' Rating from Citi | NVAX Stock News - GuruFocus
Novavax: New Vaccine, Same Old StoryStill A Sell (NASDAQ:NVAX) - Seeking Alpha
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal - Benzinga
Ruxandra Draghia-Akli, MD, PhD - Novavax
Novavax: positive results for Covid/flu vaccine - MarketScreener
Novavax's COVID-Flu Combo Shot Shows Strong Immune Response - Yahoo Finance
Novavax preps late-stage trial as COVID-flu combo vaccine matches rivals - The Pharma Letter
Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial - Pipelinereview
RFK Jr. Appoints Vaccine Critics To CDC Vaccine Panel After Firing Entire Advisory Committee: Report - Benzinga
Novavax at Goldman Sachs Healthcare Conference: Strategic Shift to R&D Focus - Investing.com Nigeria
RFK Jr. picks eight new members to CDC vaccine advisory panel - Seeking Alpha
Novavax's COVID-19-Influenza Combination and Stand-alone Influen - GuruFocus
Novavax (NVAX) Phase 3 Trial Shows Promising Results in Vaccine Study | NVAX Stock News - GuruFocus
Novavax reports positive results for COVID-19 and flu vaccine candidates By Investing.com - Investing.com South Africa
Transcript : Novavax, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 02 - marketscreener.com
Novavax (NasdaqGS:NVAX) Announces Promising Results for New Vaccine Candidates - Yahoo Finance
Novavax's Experimental COVID-19-Influenza Combo Shot Shows Immune Response Among Older Adults In Phase 3 Trial - Benzinga
Novavax (NVAX) is a Top-Ranked Momentum Stock: Should You Buy? - Yahoo Finance
Novavax's COVID-flu combo vaccine shows strong immune response in trial - Reuters
Novavax (NVAX) Reports Promising Results for COVID-19-Flu Vaccine Combo - GuruFocus
Tesla, Victoria’s Secret, Novavax rise premarket; Chewy, Gitlab fall By Investing.com - Investing.com Canada
Novavax's Covid-Influenza Combo, Standalone Flu Vaccines Show 'Robust Immune Responses' in Phase 3 Study - marketscreener.com
Novavax stock gains on data for COVID-flu shot (NVAX:NASDAQ) - Seeking Alpha
Novavax reports positive results for COVID-19 and flu vaccine candidates - Investing.com Canada
Novavax (NVAX) Reports Positive Results for COVID-Influenza Comb - GuruFocus
Novavax Reports Promising Phase 3 Vaccine Trial Results - TipRanks
Novavax (NVAX) Reports Positive Results for COVID-Influenza Combo Vaccine Trial | NVAX Stock News - GuruFocus
3.40%
2.49%
大文字化:
|
ボリューム (24 時間):